JUN 26, 2020 1:10 PM PDT

Combining Treatments to Improve Acute Myeloid Leukemia Therapy

WRITTEN BY: Jasper Cantrell

Acute myeloid leukemia (AML) is a type of blood cancer that prevents the complete maturation of stem cells. These immature stem cells accumulate in the blood and interfere with healthy blood cells. AML, being a complex disease with many different sub-types, is notably a challenge to treat. Five-year survival rates are as low as 30%. 

One of the more common subtypes of AML is characterized by the FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (FLT3-ITD) mutation. Essentially there is an extra FLT3 gene where there shouldn’t be. FLT3 is a critical player in the differentiation of stem cells into mature cells, and too much of it in the cell can lead to runaway proliferation and cancer transformation.

FLT3 tyrosine kinase inhibitors (TKI) are a class of cancer drugs that specifically target FLT3. Gilteritinib is a new TKI with fewer side effects than other FLT3 TKIs, though it only has mild anti-cancer effects. Another FLT3-TKI, sorafenib, has had success in combination with the clinical drug arsenic trioxide (ATO).  A team from the School of Medicine at Shanghai Jiao Tong University in China hypothesized that combining gilteritinib with ATO could result in a synergistic similar anti-cancer effect.

Beginning with in vitro cell assays, they found that gilteritinib, in combination with ATO, worked better at reducing cell proliferation, invasion, and increasing cell death by apoptosis than either alone in FLT3-ITD cell lines. Further investigation showed that FLT3 was not the source of the synergy between the two drugs, but genes involved in endoplasmic reticulum stress were. One gene, IRE1a, has a role in a cell death pathway called apoptosis. Gilteritinib suppressed IRE1a expression, but cotreatment with ATO rescued IRE1a expression and induced cell death in cancer cells. The synergistic anti-cancer activity was confirmed in a mouse model, which showed combination therapy could reduce tumor growth better than either drug alone.

Other studies have similarly found that the addition of ATO to an FLT3-TKI could improve a treatment’s anti-cancer effects. Gilterinitib is a second-generation FLT3-TKI, with far fewer side effects seen from other FLT3-TKIs. The team found that combining gilteritinib with ATO, or possibly any drug that induced endoplasmic reticulum stress, could result in a far better therapy than either alone. The group concluded, “Our findings may provide a new target for combination treatment and a novel theoretical basis for the treatment of FLT3-ITD positive AML patients.”

Sources: Cancer Cell International, OncLiveTV

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
JUL 28, 2020
Clinical & Molecular DX
Cancer Diagnostics Go Skin Deep
JUL 28, 2020
Cancer Diagnostics Go Skin Deep
The average adult human has between 16 and 22 square feet of skin. This multifaceted organ serves a multitude of functio ...
JUL 26, 2020
Cancer
Diet confirmed to be linked to prostate cancer risk
JUL 26, 2020
Diet confirmed to be linked to prostate cancer risk
A study published in Nutrients earlier this summer points toward diet as a key risk factor for prostate cancer ...
AUG 06, 2020
Clinical & Molecular DX
Device Diagnoses Breast Cancer in 60 Minutes
AUG 06, 2020
Device Diagnoses Breast Cancer in 60 Minutes
Researchers have created a point-of-care device that can provide diagnostic results for breast cancer in under an hour. ...
AUG 13, 2020
Clinical & Molecular DX
A Call for Bigger, Better Studies on AI Breast Cancer Diagnostics
AUG 13, 2020
A Call for Bigger, Better Studies on AI Breast Cancer Diagnostics
A staggering 1 in 8 women in the U.S. will develop an aggressive form of breast cancer in their lifetime, making it the ...
AUG 19, 2020
Immunology
Cancer Mutation Improves Chemo Drug Performance
AUG 19, 2020
Cancer Mutation Improves Chemo Drug Performance
When it comes to cancer biomarkers, it’s often the genetic signatures that are associated with poor patient outcom ...
SEP 21, 2020
Cancer
Black women have delayed and longer breast cancer treatment
SEP 21, 2020
Black women have delayed and longer breast cancer treatment
A study led by UNC Lineberger Comprehensive Cancer Center researchers has quantified the healthcare inequities in cancer ...
Loading Comments...